AstraZeneca’s (AZN) “Buy” Rating Reaffirmed at Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by research analysts at Berenberg Bank in a research report issued to clients and investors on Thursday, Digital Look reports. They presently have a £160 target price on the biopharmaceutical company’s stock. Berenberg Bank’s target price suggests a potential upside of 32.61% from the stock’s previous close.

Several other brokerages have also issued reports on AZN. Deutsche Bank Aktiengesellschaft restated a “sell” rating and set a £115 target price on shares of AstraZeneca in a research report on Wednesday. Citigroup increased their price target on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a £175 price target on shares of AstraZeneca in a research note on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of £152.17.

AstraZeneca Trading Up 0.7%

AstraZeneca stock opened at £120.66 on Thursday. AstraZeneca has a 52-week low of £107.84 and a 52-week high of £157.32. The company has a market cap of £187.13 billion, a P/E ratio of 18.06, a P/E/G ratio of 0.86 and a beta of 0.21. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The business has a 50-day simple moving average of £126.49 and a two-hundred day simple moving average of £137.02.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.